comparemela.com

Latest Breaking News On - Sirnaomics - Page 1 : comparemela.com

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising.

Lok ma chauHong kong generalHong kongPatrick luMedtech programPrnewswire sirnaomics ltdClinical translational catalyst programMedtech programmeClinical translational catalyst programmeRnaimmune incTechnology parkPositive clinical readouts validate potentialProprietary delivery platformsCement global leadershipGuangzhou facilityTranslational catalyst programme

Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

/PRNewswire/ Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical.

Patrick luMichael molyneauxGroup or sirnaomicsGroup galaheadPrnewswire sirnaomics ltdAtrial fibrillationExecutive directorChief medical officerChief executive officer

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine

/PRNewswire/ RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based.

Dong shenUnited statesPatrick luRnaimmune incUnited states food drug administrationSirnaomics ltdUnited states foodDrug administrationInvestigational new drugStock code

Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

/PRNewswire/ Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a leading.

United statesRichardw welchPatrick luGroup or sirnaomicsSirnaomics ltdStock codeChief executiveVice presidentBased therapeuticPolypeptide nanoparticleCancer therapeuticsSquamous cell carcinomaBasal cell carcinomaKey clinical study readoutsDeveloping robust processesEnable large scale manufacturing

HSBC Maintains Sirnaomics (2257 HK) at Buy Rating with Target Price of HKD90 00; 61% Upside

DJ HSBC Maintains Sirnaomics (2257.HK) at Buy Rating with Target Price of HKD90.00; 61% Upside EQS Newswire / 16/01/2023 / 17:53 UTC+8 HSBC initiates coverage of Sirnaomics, lowers the target price

Financial pressBuy ratingTarget priceFinancial press releaseDow jones newswires

vimarsana © 2020. All Rights Reserved.